Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1-receptor antagonist gene but not with polymorphisms in the interleukin-1β gene

Journal of Bone and Mineral Research

Volumn 15, Issue 3, 2000, Pages 402-414

  Langdahl, Bente L ^a   Løkke, Elsebet ^b   Carstens, Mette ^b   Stenkjær, Lise Lotte ^b   Eriksen, Erik Fink ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

Bone mass; Bone turnover; IL 1 receptor antagonist; IL 1 ; Osteoporosis; Polymorphism

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BASE MISPAIRING; BONE TURNOVER; EXON; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; OSTEOPOROSIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; TANDEM REPEAT; VERTEBRA FRACTURE;

EID: 0034006946     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2000.15.3.402     Document Type: Article

References (48)

1. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberi S 1987 Genetic deteminants of bone mass in adults. A twin study. J Clin Invest 80:706-710.
2. Langdahl BL, Knudsen JY, Jensen HK, Gregersen N, Eriksen EF 1997 A sequence variation: 713-8delC in the transforming growth factor-β1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone 20:289-294.
3. Grant SFA, Reid DM, Blake G, Herd R, Fogelman I, Ralston SH 1996 Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I α 1 gene. Nat Genet 14:203-205.
4. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA 1994 Prediction of bone density from vitamin D receptor alleles. Nature 367:284-287.
5. Kobayashi S, Inoue S, Hosoi T, Ouchi Y, Shiraki M, Orimo H 1996 Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res 11:306-311.
6. Grant SFA, Nguyen TV, Howard GM, White C, Morrison NA, Ralston SH, Eisman JA 1997 Genetic linkage between a polymorphism in the collagen I α I gene and bone mineral density: A twin study. Bone 20(Suppl 4):7S.
7. Uitterlinden AG, Burger H, Huang Q, Yue F, McGuigan FEA, Grant SFA, Hofman A, van Leeuwen JPTM, Pols HAP, Ralston SH 1998 Relation of alleles of the collagen type Ia1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med 338:1016-1021.
8. Ralston SH 1994 Analysis of gene expression in human bone biopsies by polymerase chain reaction: Evidence for enhanced cytokine expression in postmenopausal osteoporosis. J Bone Miner Res 9:883-890.
9. Linkhart TA, MacCharles DC 1992 Interleukin-1 stimulates release of insulin-like growth factor-I from neonatal mouse calvaria by a prostaglandin synthesis-dependent mechanism. Endocrinology 131:2297-2305.
10. Passeri G, Girasole G, Jilka RL, Manolagas SC 1993 Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology 133:822-828.
11. Khosla S, Peterson JM, Egan K, Jones JD, Riggs BL 1994 Circulating cytokine levels in osteoporotic and normal women. J Clin Endocrinol Metab 79:707-711.
12. Kimble RB, Matayoshi AB, Vannice JL, Kung VT, Williams C, Pacifici R 1995 Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology 136:3054-3061.
13. Lennard A, Gorman P, Carrier M, Griffiths S, Scotney H, Sheer D, Solari R 1992 Cloning and chromosome mapping of the human interleukin-1 receptor antagonist gene. Cytokine 4: 83-89.
14. Haskill JS, Martin G, Van.Le L, Morris J, Peace A, Bigler CF, Jaffe GJ, Hammerberg C, Sporn SA, Fong S, Arend WP, Ralph P 1991 cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc Natl Acad Sci U S A 88:3681-3685.
15. Butcher C, Steinkasserer A, Tejura S, Lennard A 1994 Comparison of two promotors controlling expression of secreted or intracellular IL-1 receptor antagonist. J Immunol 153:701-711.
16. Clay FE, Tarlow JK, Cork MJ, Cox A, Nicklin MJH, Duff GW 1996 Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment. Hum Genet 97:723-726.
17. Guasch JF, Bertina RM, Reitsma PH 1996 Five novel intragenic dimorphisms in the human interleukin-1 genes combine to high informativity. Cytokine 8:598-602.
18. Danis VA, Millington M, Hyland VJ, Grennan D 1995 Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 99:303-310.
19. Bensi G, Raugei G, Palla E, Carinci V, Buonamassa DT, Melli M 1987 Human interleukin-1 beta gene. Gene 52:95-101.
20. Clark BD, Collins KL, Gandy MS, Webb AC, Auron PE 1986 Genomic sequence for human prointerleukin 1 beta: Possible evolution from a reverse transcribed prointerleukin 1 alpha gene. Nucleic Acids Res 14:7897-7914.
21. di Giovine FS, Takhsn E, Blakemore AIF, Duff GW 1992 Single base polymorphism at -511 in the human interleukin-1 β gene (IL1 β). Hum Mol Genet 1:450.
22. Pociot F, Mølvig J, Wogensen L, Worsaae H, Nerup J 1992 A TaqI polymorphism in the human interleukin-1 β(IL-1 β) gene correlates with IL-1 β secretion in vitro. Eur J Clin Invest 22:396-402.
23. Genant HK, Grampp S, Glüer CC, Faulkner KG, Jergas M, Engelke K, Hagiwara S, vanKuijk C 1994 Universal standardization for dual x-ray absorptiometry: Patient and phantom cross-calibration results. J Bone Min Res 9:1503-1514.
24. Risteli J, Niemi S, Elomaa T, Risteli L 1991 Bone resorption assay based on a peptide liberated during type I collagen degradation. J Bone Miner Res 6:S251.
25. Brixen K, Nielsen HK, Eriksen EF, Charles P, Mosekilde L 1989 Efficacy of wheat germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralization rate: Comparison to serum total alkaline phosphatase and serum bone Gla-protein. Calcif Tissue Int 44:93-98.
26. Nielsen HK, Laurberg P, Brixen K, Mosekilde L 1991 Relation between the diurnal variation in serum osteocalcin, and the variation in serum concentrations of cortisol, PTH(1-84) and ionized calcium in normal individuals. Acta Endocrinol 124: 391-398.
27. Melkko J, Niemi S, Risteli L, Risteli J 1990 Radioimmunoassay for the carboxyterminal propetide of human type I procollagen. Clin Chem 36:1328-1332.
28. Kunkel LM, Smith KD, Boyer SH 1977 Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants. Proc Natl Acad Sci U S A 74:1245-1249.
29. Hayashi K 1992 PCR-SSCP: A Method for Detection of Mutations. GATA 9:73-79.
30. Tarlow JK, Blakemore AIF, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW 1993 Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by varible numbers of an 86-bp tandem repeat. Hum Genet 91:403-404.
31. Heresbach D, Alizadeh M, Dabadie A, Le.Berre N, Colombel JF, Yaouanq J, Bretagne JF, Semana G 1997 Significance of interleukin-1 β og interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases. Am J Gastroenterol 92:1164-1168.
32. Huang D, Pirskanen R, Hjelmström P, Lefvert AK 1998 Polymorphisms in IL-1 β og IL-1 receptor antagonist genes are associated with myasthenia gravis. J Neuroimmunol 81:76-81.
33. Tarlow L, Pociot F, Hansen PM, Rossing P, Nielsen FS, Hansen BV, Parving H-H 1997 Polymorphisms in the interleukin-1 gene cluster do not contribute to the genetic susceptibility og diabetic nephropathy in caucasian patients with IDDM. Diabetes 46:1075-1076.
34. Mandrup-Poulsen T, Pocoit F, Mølvig J, Shapiro L, Nilsson P, Emdal T, Roder M, Kjems LL, Dinarello CA, Nerup J 1994 Monokine antagonism is reduced in patients with IDDM. Diabetes 43:1242-1247.
35. Danis VA, Millington M, Huang Q, Hyland V, Grennan D 1994 Lack of association between an interleukin-1 receptor antagonist gene polymorphism and systemic lupus erythematosus. Dis Markers 12:135-139.
36. Santtila S, Savinainen K, Hurme M 1998 Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 47:195-198.
37. Tarlow JK, Cork MJ, Clay FE, Schmitt-Egenolf M, Crane AM, Stierle C, Boehncke W-H, Eiermann TH, Blakemore AIF, Bleehen SS, Sterry W, Duff GW 1997 Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis. Br J Dermatol 136:147-148.
38. Keen RW, Woodford-Richens KL, Lanchbury JS, Spector TD 1998 Allelic variation at the interleukin-1 receptor antagonist gene is associated with early postmenopausal bone loss at the spine. Bone 23:367-371.
39. Abrahamsen B, Bendtzen K, Beck-Nielsen H 1997 Cytokines and T-lymphocyte subsets in healthy post-menopausal women: Estrogen retards bone loss without affecting the release of IL-1 or IL-1ra. Bone 20:251-258.
40. Blakemore AIF, Cox A, Gonzales A-M, Maskill JK, Hughes ME, Wilson RM, Ward JD, Duff GW 1996 Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet 97:369-374.
41. Blakemore AIF, Tarlow JK, Cork MJ, Gordon C, Emety P, Duff GW 1994 Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythrmatosus. Arthritis Rheum 37:1380-1385.
42. Crusius JBA, Pena AS, Oosten BWv, Bioque G, Garcia A, Dijkstra CD, Polman CH 1995 Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet 346:979-980.
43. Liu Z-H, Cheng Z-H, Yu Y-S, Tang Z, Li L-S 1997 Interleukin-1 receptor antagonist allele: Is it a genetic link between Henoch-Schönlein nephritis and IgA nephropathy? Kidney Int 51:1938-1942.
44. Tarlow JK, Clay FE, Cork MJ, Blakemore AIF, McDonagh AJG, Messenger AG, Duff GW 1994 Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. J Invest Dermatol 103:387-390.
45. Huang W-X, He B, Hillert J 1996 An interleukin 1-receptor-antagonist gene polymorphism is not associated with multiple sclerosis. J Neuroimmunol 67:143-144.
46. Demeter J, Messer G, Rämisch S, Mee JB, di.Giovine FS, Schmid M, Herrmann F, Porzsolt F 1996 Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies. Cytokines Mol Ther 2:239-242.
47. Cuddihy RM, Bahn RS 1996 Lack of an association between alleles of interleukin-1 alpha and interleukin-1 receptor antagonist genes and Graves' disease in a North American Caucasian population. J Clin Endocrinol Metab 81:4476-4478.
48. Bioque G, Crusius JBA, Koutroubakis I, Bouma G, Kostense PJ, Meuwissen SGM, Pena AS 1995 Allelic polymorphism in IL-1 β and IL-1 receptor antogonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol 102:379-383.